Clinical Trials Browser

Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Cisplatin × Clear all

NCT05498220 2025-09-02

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse